Lipocine Announces License and Supply Agreement for TLANDO in Brazil

Announces License and Supply Agreement for TLANDO in Brazil

LAKE CITY, May 6, 2025 / PRNewswire / - Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its

proprietary technology platform to enable effective oral delivery of therapeutics, today announced that it has entered into license

and supply agreement with Ach Laborat rios Farmac uitcos S.A (Ach ) granting exclusive rights to market

market for prescription testosterone products in Brazil is substantial and rapidly growing with compound annual growth rate (CAGR) of

34% from 2019 to 2023 and no oral testosterone therapy registered in Brazil.

are pleased to partner with Ach , one of the leaders in the Brazilian pharmaceutical market, to further expand the opportunity

for TLANDO," said Mahesh Patel, CEO of Lipocine. "Brazil represents an important new growth market, and Ach 's

established commercial capabilities and proven regulatory expertise make them an ideal partner to bring TLANDO to patients in Brazil."

the terms of the agreement, Lipocine has received an upfront payment and is eligible to receive additional payments upon the achievement

of certain regulatory milestones and royalties on net sales. Ach assumes full responsibility for the regulatory submission and

approval process in Brazil.

is approved by the US FDA as a testosterone replacement therapy (TRT) in adult males indicated for conditions associated

with a deficiency or absence of endogenous testosterone: primary hypogonadism (congenital or acquired) and hypogonadotropic hypogonadism

(congenital or acquired). It was developed using Lipocine's proprietary Lip'ral drug delivery technology platform.

full prescribing information, please visit www.TLANDO.com.

Ach is a Brazilian pharmaceutical company founded nearly 60 years ago with a mission to improve people's

lives. A leader in the prescription market in Brazil, Ach 's portfolio also includes solutions in generic medicines and over-the-counter

(OTC) products. This success is driven by a commitment to excellence and a focus on investments in in-house research and development (R&D),

partnerships for open innovation, and in-licensed products.

Ach is recognized as a top-of-mind company and a brand of choice among Brazilian healthcare professionals,

with over 350 brands and 900 drug presentations across more than 150 therapeutic categories and 30 medical specialties. Today, Ach 's

products reach more than 20 countries across Latin America, Africa, Asia, and Europe, in addition to its home base in Brazil.

is a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics. Lipocine

has drug candidates in development as well as drug candidates for which we are exploring partnerships. Our drug candidates represent

enablement of differentiated, patient friendly oral delivery options for favorable benefit to risk profile which target large addressable

markets with significant unmet medical needs.

clinical development candidates include: LPCN 1154, oral brexanolone, for the potential treatment of postpartum depression, LPCN 2101

for the potential treatment of epilepsy, LPCN 2203 an oral candidate targeted for the management of essential tremor, LPCN 2401 an oral

proprietary anabolic androgen receptor agonist, as an adjunct therapy to incretin mimetics, as an aid for improved body composition in

obesity management and LPCN 1148, a novel androgen receptor agonist prodrug for oral administration targeted for the management of symptoms

associated with liver cirrhosis. Lipocine is exploring partnering opportunities for LPCN 1107, our candidate for prevention of preterm

birth, LPCN 1154, for rapid relief of postpartum depression, LPCN 2401 for obesity management, LPCN 1148, for the management of decompensated

cirrhosis, and LPCN 1144, our candidate for treatment of metabolic dysfunction-associated steatohepatitis (MASH). TLANDO, a novel oral

prodrug of testosterone containing testosterone undecanoate developed by Lipocine, is approved by the FDA for conditions associated with

a deficiency of endogenous testosterone, also known as hypogonadism, in adult males. For more information, please visit www.lipocine.com.

release contains "forward-looking statements" that are made pursuant to the safe harbor provisions of the Private Securities

Litigation Reform Act of 1995 and include statements that are not historical facts regarding our product candidates and related clinical

trials, our development of our product candidates and related efforts with the FDA, including with respect to LPCN 1154, our P3 safety

and efficacy study relating to LPCN 1154, the timing and potential results of the safety and efficacy study relating to LPCN 1154, potential

partnering of our product candidates with third parties, and the potential uses and benefits of our product candidates. Investors are

cautioned that all such forward-looking statements involve risks and uncertainties, including, without limitation, the risks that we

may not be successful in developing product candidates, we may not have sufficient capital to complete the development processes for

our product candidates or we may decide to allocate our available capital to other product candidates, we may not be able to enter into

partnerships or other strategic relationships to monetize our non-core assets, safety and efficacy studies, including those relating

to LPCN 1154, may not be successful or may not provide results that would support the submission of a NDA, the FDA may not approve any

of our products, risks related to our products, expected product benefits not being realized, clinical and regulatory expectations and

plans not being realized, new regulatory developments and requirements, risks related to the FDA approval process including the receipt

of regulatory approvals and our ability to utilize a streamlined approval pathway for LPCN 1154, the results and timing of clinical trials,

patient acceptance of Lipocine's products, the manufacturing and commercialization of Lipocine's products, and other risks

detailed in Lipocine's filings with the SEC, including, without limitation, its Form 10-K and other reports on Forms 8-K and 10-Q,

all of which can be obtained on the SEC website at www.sec.gov. Lipocine assumes no obligation to update or revise publicly any

forward-looking statements contained in this release, except as required by law.

further information: Krista Fogarty, Phone: (801) 994-7383, kf@lipocine.com,

PJ Kelleher, Phone: (617) 430-7579, pkelleher@lifesciadvisors.com